Edgar Filing: Aghazadeh Behzad - Form 4

Aghazadeh Form 4												
November 1	5, 2017											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION							MMISSION	OMB APPROVAL				
Check th		STATES			, D.C. 2054			VIIVIISSION	OMB Number:	3235-0287		
if no lon subject t Section Form 4 o Form 5 obligatio	ger o 16. or Filed pu	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,								Expires:January 31, 2005Estimated average burden hours per response0.5		
may con See Insti 1(b).	tinue. Section 176				ding Compa t Company 4			035 or Section				
(Thin of Type	Responses											
1. Name and Address of Reporting Person [*] Aghazadeh Behzad			Symbol		d Ticker or Tra		Iss	5. Relationship of Reporting Person(s) to Issuer				
		IMMUNOMEDICS INC [IMMU]						eck all applicable)				
	(First) (SIO SELECT AD W. 45TH STREE			f Earliest T Day/Year) 2017	ransaction		_	low)	_X_ 10% tle _X_ Othe below) e Remarks			
				endment, D nth/Day/Yea	ate Original r)		Ap _X	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative Sec	uritie	s Acquir	ed, Disposed of,	or Beneficiall	y Owned		
1.Title of Security (Instr. 3)	2. Transaction Data (Month/Day/Year)		ned 1 Date, if	3.	4. Securities . onor Disposed o (Instr. 3, 4 an	Acquin of (D) d 5) (A)	-	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock,				Code V	Amount	or (D)	Price	(Instr. 3 and 4)				
\$0.01 par value per share (the "Common Stock")	11/14/2017			Р	1,150,000	A	\$ 10.39 (<u>3)</u>	15,889,461	Ι	See footnotes (1) (2)		
Common Stock	11/15/2017			Р	175,000	А	\$ 10.97 (4)	16,064,461	Ι	See footnotes (1) (2)		

Edgar Filing: Aghazadeh Behzad - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	isable and	7. Title	e and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onNumber	Expiration Da	ate	Amour	nt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underl	ying	Security	Secu
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securit	ties	(Instr. 5)	Bene
	Derivative				Securities			(Instr. 2	3 and 4)		Owne
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date	Expiration		or Number		
						Exercisable Date	Date		of		
				Code V	(Λ) (D)				of Shares		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address		Relati						
Reporting of the Funct Fruitess	Director	10% Owner	Officer	Other				
Aghazadeh Behzad C/O VENBIO SELECT ADVISOR LLC 120 W. 45TH STREET, 28TH FLOOR NEW YORK, NY 10036	Х	Х		See Remarks				
Signatures								
venBio Select Advisor LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer								
**Signature of Reporting Person								
/s/ Behzad Aghazadeh					11/15/2017			

/s/ Behzad Aghazadeh

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the

(1) Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.

(2)

Date

Edgar Filing: Aghazadeh Behzad - Form 4

The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$10.2 to

(3) \$10.8403 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$10.6584 to \$11.3049 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or staff of the Securities

(4) \$11.5049 inclusive. The Reporting Fersons undertake to provide to the issuer, any security holder of the issuer, or start of the securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth herein.

Remarks:

The Investment Manager may be deemed a director by deputization of Immunomedics, Inc. (the "Issuer") by virtue of the fact

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.